DGX vs LH
DGX: Quest Diagnostics is the largest clinical laboratory testing company in the U.S., providing diagnostic insights to healthcare providers, employers, and consumers to improve health outcomes and enable value-based care. LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities.
Side-by-side fundamentals
| Metric | DGX | LH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $209.83 | $281.46 | |
| Market cap as of 2026-07-23 | $23.0B | $23.1B | |
| P/E as of 2026-07-23 | 22.47 | 24.51 | DGX lower |
| PEG as of 2026-07-23 | 2.41 | 2.76 | DGX lower |
| Net margin as of 2026-07-23 | +9.1% | +6.7% | DGX higher |
| Gross margin as of 2026-07-23 | +33.3% | +28.8% | DGX higher |
| Operating margin as of 2026-07-23 | +14.3% | +10.2% | DGX higher |
| ROE as of 2026-07-23 | +14.1% | +10.9% | DGX higher |
| ROA as of 2026-07-23 | +6.3% | +5.1% | DGX higher |
| Debt / equity as of 2026-07-23 | 0.77 | 0.73 | LH lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.0% | +7.3% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | +5.6% | LH higher |
| Dividend yield as of 2026-07-23 | +1.7% | +1.0% | DGX higher |
| Dividend streak (yrs) SEC XBRL | 5 | 4 | DGX higher |
| Beta as of 2026-07-23 | 0.56 | 0.88 | |
| 1-year return as of 2026-07-22 close | +24.3% | +11.7% | DGX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.